Risk of Sudden Death and Outcome in Patients With Hypertrophic Cardiomyopathy With Benign Presentation and Without Risk Factors

Published:February 14, 2014DOI:https://doi.org/10.1016/j.amjcard.2014.01.435
      Patients with hypertrophic cardiomyopathy (HC) are reported to have a mortality rate of about 1.0% per year, and those patients without sudden death risk factors and with no or mild symptoms are generally considered to have a benign clinical presentation. However, the risk of sudden death and the outcome in this latter subgroup have not been investigated systematically and remain unresolved. We assessed the risk of sudden death and outcome in 653 consecutive patients with HC without risk factors and with no or mild symptoms. Over a median follow-up of 5.3 years, 35 patients (5.4%) died of HC-related causes. Mean age at death was 46 ± 20 years in patients who died suddenly and 66 ± 15 and 72 ± 9 years, respectively, in patients who died of heart failure or stroke. Event rate was 0.6% per year for sudden death, 0.2% per year for heart failure death, and 0.1% per year for stroke-related death. Sudden death risk was independently and inversely related to age, and risk of heart failure or stroke death was directly related to age (p = 0.020). At 10 years after the initial evaluation, sudden death risk was 5.9%, with sudden death rate being the lowest (0.3% per year) in patients with normal left atrial dimension (≤40 mm). In conclusion, in patients with HC without conventional risk factors and with no or mild symptoms, the risk of sudden death was not negligible, with an event rate of 0.6% per year. Heart failure and stroke-related death were less common and largely confined to older patients. These results underscore the need for a more accurate assessment of the sudden death risk in patients with HC.
      To read this article in full you will need to make a payment

      References

        • Maron B.J.
        • McKenna W.J.
        • Danielson G.K.
        • Kappenberger L.J.
        • Kuhn H.J.
        • Seidman C.E.
        • Shah P.M.
        • Spencer III, W.H.
        • Spirito P.
        • Ten Cate F.J.
        • Wigle E.D.
        American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines.
        J Am Coll Cardiol. 2003; 42: 1687-1713
        • Gersh B.J.
        • Maron B.J.
        • Bonow R.O.
        • Dearani J.A.
        • Fifer M.A.
        • Link M.S.
        • Naidu S.S.
        • Nishimura R.A.
        • Ommen S.R.
        • Rakowski H.
        • Seidman C.E.
        • Towbin J.A.
        • Udelson J.E.
        • Yancy C.W.
        2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2011; 58: e212-e260
        • Maron B.J.
        • Shen W.K.
        • Link M.S.
        • Epstein A.E.
        • Almquist A.K.
        • Daubert J.P.
        • Bardy G.H.
        • Favale S.
        • Rea R.F.
        • Boriani G.
        • Estes 3rd, N.A.
        • Spirito P.
        Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
        N Engl J Med. 2000; 342: 365-373
        • Maron B.J.
        • Spirito P.
        • Shen W.K.
        • Haas T.S.
        • Formisano F.
        • Link M.S.
        • Epstein A.E.
        • Almquist A.K.
        • Daubert J.P.
        • Lawrenz T.
        • Boriani G.
        • Estes III, N.A.
        • Favale S.
        • Piccininno M.
        • Winters S.L.
        • Santini M.
        • Betocchi S.
        • Arribas F.
        • Sherrid M.V.
        • Buja G.
        • Semsarian C.
        • Bruzzi P.
        Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
        JAMA. 2007; 298: 405-412
        • Spirito P.
        • Bellone P.
        • Harris K.M.
        • Bernabò P.
        • Bruzzi P.
        • Maron B.J.
        Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy.
        N Engl J Med. 2000; 342: 1778-1785
        • Elliott P.M.
        • Poloniecki J.
        • Dickie S.
        • Sharma S.
        • Monserrat L.
        • Varnava A.
        • Mahon N.G.
        • McKenna W.J.
        Sudden death in hypertrophic cardiomyopathy: identification of high risk patients.
        J Am Coll Cardiol. 2000; 36: 2212-2218
        • Elliott P.M.
        • Gimeno Jr., B.
        • Mahon N.G.
        • Poloniecki J.D.
        • McKenna W.J.
        Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy.
        Lancet. 2001; 357: 420-424
        • Spirito P.
        • Autore C.
        • Rapezzi C.
        • Bernabò P.
        • Badagliacca R.
        • Maron M.S.
        • Bongioanni S.
        • Coccolo F.
        • Mark Estes N.A.
        • Barillà C.S.
        • Biagini E.
        • Quarta G.
        • Conte M.R.
        • Bruzzi P.
        • Maron B.J.
        Syncope and risk of sudden death in hypertrophic cardiomyopathy.
        Circulation. 2009; 119: 1703-1710
        • Maron B.J.
        Sudden death in hypertrophic cardiomyopathy. Contemporary insights and strategies for risk stratification and prevention.
        Circulation. 2010; 121: 445-456
        • Maron B.J.
        • Gardin J.M.
        • Flack J.M.
        • Gidding S.S.
        • Kurosaki T.T.
        • Bild D.E.
        Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4,111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults.
        Circulation. 1995; 92: 785-789
        • Maron B.J.
        • Olivotto I.
        • Bellone P.
        • Conte M.R.
        • Cecchi F.
        • Flygenring B.P.
        • Casey S.A.
        • Gohman T.E.
        • Bongioanni S.
        • Spirito P.
        Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy.
        J Am Coll Cardiol. 2002; 39: 301-307
        • Maron B.J.
        • Olivotto I.
        • Spirito P.
        • Casey S.A.
        • Bellone P.
        • Gohman T.E.
        • Graham K.J.
        • Burton D.A.
        • Cecchi F.
        Epidemiology of hypertrophic cardiomyopathy related death: revisited in a large non-referral-based patient population.
        Circulation. 2000; 102: 858-864
        • Spirito P.
        • Chiarella F.
        • Carratino L.
        • Berisso M.Z.
        • Bellotti P.
        • Vecchio C.
        Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population.
        N Engl J Med. 1989; 320: 749-755
        • Cecchi F.
        • Olivotto I.
        • Montereggi A.
        • Santoro G.
        • Dolara A.
        • Maron B.J.
        Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population.
        J Am Coll Cardiol. 1995; 26: 1529-1536
        • Cannan C.R.
        • Reeder G.S.
        • Bailey K.R.
        • Melton L.J.
        • Gersh B.J.
        Natural history of hypertrophic cardiomyopathy: a population-based study, 1976 through 1990.
        Circulation. 1995; 92: 2488-2495
        • Maron B.J.
        • Casey S.A.
        • Poliac L.C.
        • Gohman T.E.
        • Almquist A.K.
        • Aeppli D.M.
        Clinical course of hypertrophic cardiomyopathy in a regional United States cohort.
        JAMA. 1999; 281: 650-655
        • Adabag A.S.
        • Maron B.J.
        • Appelbaum E.
        • Harrigan C.J.
        • Buros J.L.
        • Gibson C.M.
        • Lesser J.R.
        • Hanna C.A.
        • Udelson J.E.
        • Manning W.J.
        • Maron M.S.
        Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance.
        J Am Coll Cardiol. 2008; 51: 1369-1374
        • Maron M.S.
        • Appelbaum E.
        • Harrigan C.J.
        • Buros J.
        • Gibson C.M.
        • Hanna C.
        • Lesser J.R.
        • Udelson J.E.
        • Manning W.J.
        • Maron B.J.
        Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy.
        Circ Heart Fail. 2008; 1: 184-191
        • Rubinshtein R.
        • Glockner J.F.
        • Ommen S.R.
        • Araoz P.A.
        • Ackerman M.J.
        • Sorajja P.
        • Bos J.M.
        • Tajik A.J.
        • Valeti U.S.
        • Nishimura R.A.
        • Gersh B.J.
        Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy.
        Circ Heart Fail. 2010; 3: 51-58
        • Salerno M.
        • Kramer C.M.
        Prognosis in hypertrophic cardiomyopathy with contrast-enhanced cardiac magnetic resonance: the future looks bright.
        J Am Coll Cardiol. 2010; 56: 888-889
        • Maron M.S.
        • Olivotto I.
        • Betocchi S.
        • Casey S.A.
        • Lesser J.R.
        • Losi M.A.
        • Cecchi F.
        • Maron B.J.
        Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy.
        N Engl J Med. 2003; 348: 295-303
        • Autore C.
        • Bernabò P.
        • Barillà C.S.
        • Bruzzi P.
        • Spirito P.
        The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms.
        J Am Coll Cardiol. 2005; 45: 1076-1080
        • Sorajja P.
        • Nishimura R.A.
        • Gersh B.J.
        • Dearani J.A.
        • Hodge D.O.
        • Wiste H.J.
        • Ommen S.R.
        Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a long-term follow-up study.
        J Am Coll Cardiol. 2009; 54: 234-241

      Linked Article